Xencor Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Xencor Inc 公司

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Xencor Inc简介



公司代码XNCR

公司名称Xencor Inc

上市日期Dec 03, 2013

CEODahiyat (Bassil I)

员工数量250

证券类型Ordinary Share

年结日Dec 03

公司地址465 N. Halstead St.

城市PASADENA

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编91107

电话16263055900

网址https://xencor.com/

公司代码XNCR

上市日期Dec 03, 2013

CEODahiyat (Bassil I)

Xencor Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

224.60K

+5322.00%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+16209.00%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-3750.00%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+10693.00%

Mr. Todd E. Simpson

Independent Director

13.69K

+13686.00%

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+10693.00%

Dr. Bassil I. Dahiyat, Ph.D.

President, Chief Executive Officer, Founder and Director

--

Dr. A. Bruce Montgomery, M.D.

Lead Independent Director

--

Dr. Kevin C. Gorman, Ph.D.

Independent Director

--

Dr. Ellen Gwen Feigal, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

224.60K

+5322.00%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+16209.00%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-3750.00%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+10693.00%

Mr. Todd E. Simpson

Independent Director

13.69K

+13686.00%

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+10693.00%

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Royalties

21.00M

0.00%

Milestone

0.00

0.00%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Royalties

21.00M

0.00%

Milestone

0.00

0.00%

股东统计

更新时间: 13 小时前

持股股东

股东类型

持股股东

占比

PRIMECAP Management Company

14.95%

BlackRock Institutional Trust Company, N.A.

14.82%

The Vanguard Group, Inc.

10.01%

RTW Investments L.P.

8.71%

EcoR1 Capital, LLC

8.60%

其他

42.90%

持股股东

占比

PRIMECAP Management Company

14.95%

BlackRock Institutional Trust Company, N.A.

14.82%

The Vanguard Group, Inc.

10.01%

RTW Investments L.P.

8.71%

EcoR1 Capital, LLC

8.60%

其他

42.90%

股东类型

持股股东

占比

Investment Advisor

56.73%

Investment Advisor/Hedge Fund

36.45%

Hedge Fund

18.64%

Research Firm

4.71%

Individual Investor

1.34%

Venture Capital

1.05%

Pension Fund

0.91%

Bank and Trust

0.36%

Sovereign Wealth Fund

0.08%

机构持股



更新时间: 1月21日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q4

364

84.79M

119.03%

--

2025Q4

446

84.30M

118.05%

-5.40M

2025Q3

434

80.43M

112.65%

-6.04M

2025Q2

437

81.68M

114.52%

-1.81M

2025Q1

459

80.70M

113.40%

-3.00M

2024Q4

454

76.54M

108.64%

-2.55M

2024Q3

455

73.66M

105.55%

+3.66M

2024Q2

436

65.64M

106.20%

-4.06M

2024Q1

431

66.91M

108.52%

-498.74K

2023Q4

420

65.39M

107.20%

-1.62M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

PRIMECAP Management Company

10.68M

14.95%

+147.70K

+1.40%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.58M

14.82%

-92.56K

-0.87%

Sep 30, 2025

The Vanguard Group, Inc.

7.17M

10.04%

+80.65K

+1.14%

Nov 28, 2025

RTW Investments L.P.

6.22M

8.71%

+3.82M

+158.90%

Sep 30, 2025

EcoR1 Capital, LLC

6.14M

8.6%

--

Sep 30, 2025

BVF Partners L.P.

4.62M

6.47%

+1.88M

+68.58%

Oct 17, 2025

State Street Investment Management (US)

3.67M

5.14%

-143.78K

-3.77%

Sep 30, 2025

TCG Crossover Management, LLC

2.45M

3.43%

--

Sep 30, 2025

Geode Capital Management, L.L.C.

1.73M

2.42%

+25.16K

+1.48%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

1.59M

2.23%

-191.61K

-10.76%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Genomics Immunology and Healthcare ETF

2.09%

Tema Oncology ETF

1.16%

Virtus LifeSci Biotech Clinical Trials ETF

1.06%

Invesco NASDAQ Future Gen 200 ETF

0.97%

Invesco S&P SmallCap Health Care ETF

0.64%

ALPS Medical Breakthroughs ETF

0.43%

State Street SPDR S&P Biotech ETF

0.33%

Inspire Small/Mid Cap ESG ETF

0.3%

Direxion Daily S&P Biotech Bull 3X Shares

0.15%

ProShares Ultra Nasdaq Biotechnology

0.15%

iShares Genomics Immunology and Healthcare ETF

占比2.09%

Tema Oncology ETF

占比1.16%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.06%

Invesco NASDAQ Future Gen 200 ETF

占比0.97%

Invesco S&P SmallCap Health Care ETF

占比0.64%

ALPS Medical Breakthroughs ETF

占比0.43%

State Street SPDR S&P Biotech ETF

占比0.33%

Inspire Small/Mid Cap ESG ETF

占比0.3%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.15%

ProShares Ultra Nasdaq Biotechnology

占比0.15%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据